NASDAQ:ORIC

ORIC Pharmaceuticals Competitors

$19.69
-1.88 (-8.72 %)
(As of 04/12/2021 12:00 AM ET)
Add
Compare
Today's Range
$19.44
Now: $19.69
$22.21
50-Day Range
$21.57
MA: $28.38
$36.24
52-Week Range
$18.60
Now: $19.69
$40.81
Volume219,038 shs
Average Volume285,956 shs
Market Capitalization$722.52 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

ORIC Pharmaceuticals (NASDAQ:ORIC) Vs. TARO, OPK, CORT, ITCI, DCPH, and RCKT

Should you be buying ORIC stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to ORIC Pharmaceuticals, including Taro Pharmaceutical Industries (TARO), OPKO Health (OPK), Corcept Therapeutics (CORT), Intra-Cellular Therapies (ITCI), Deciphera Pharmaceuticals (DCPH), and Rocket Pharmaceuticals (RCKT).

ORIC Pharmaceuticals (NASDAQ:ORIC) and Taro Pharmaceutical Industries (NYSE:TARO) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, earnings, risk and valuation.

Valuation & Earnings

This table compares ORIC Pharmaceuticals and Taro Pharmaceutical Industries' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ORIC PharmaceuticalsN/AN/AN/AN/AN/A
Taro Pharmaceutical Industries$644.77 million4.31$244.24 million$6.3511.43

Taro Pharmaceutical Industries has higher revenue and earnings than ORIC Pharmaceuticals.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for ORIC Pharmaceuticals and Taro Pharmaceutical Industries, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ORIC Pharmaceuticals01602.86
Taro Pharmaceutical Industries00103.00

ORIC Pharmaceuticals presently has a consensus price target of $43.7143, suggesting a potential upside of 122.01%. Taro Pharmaceutical Industries has a consensus price target of $81.00, suggesting a potential upside of 11.59%. Given ORIC Pharmaceuticals' higher possible upside, equities research analysts plainly believe ORIC Pharmaceuticals is more favorable than Taro Pharmaceutical Industries.

Insider & Institutional Ownership

73.4% of ORIC Pharmaceuticals shares are held by institutional investors. Comparatively, 11.2% of Taro Pharmaceutical Industries shares are held by institutional investors. 13.8% of Taro Pharmaceutical Industries shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares ORIC Pharmaceuticals and Taro Pharmaceutical Industries' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ORIC PharmaceuticalsN/AN/AN/A
Taro Pharmaceutical Industries-45.94%10.36%8.38%

Summary

Taro Pharmaceutical Industries beats ORIC Pharmaceuticals on 5 of the 9 factors compared between the two stocks.

ORIC Pharmaceuticals (NASDAQ:ORIC) and OPKO Health (NASDAQ:OPK) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, earnings, risk and valuation.

Valuation & Earnings

This table compares ORIC Pharmaceuticals and OPKO Health's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ORIC PharmaceuticalsN/AN/AN/AN/AN/A
OPKO Health$901.90 million3.02$-314,920,000.00($0.41)-9.90

ORIC Pharmaceuticals has higher earnings, but lower revenue than OPKO Health.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for ORIC Pharmaceuticals and OPKO Health, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ORIC Pharmaceuticals01602.86
OPKO Health00203.00

ORIC Pharmaceuticals presently has a consensus price target of $43.7143, suggesting a potential upside of 122.01%. OPKO Health has a consensus price target of $9.00, suggesting a potential upside of 121.67%. Given ORIC Pharmaceuticals' higher possible upside, equities research analysts plainly believe ORIC Pharmaceuticals is more favorable than OPKO Health.

Insider & Institutional Ownership

73.4% of ORIC Pharmaceuticals shares are held by institutional investors. Comparatively, 28.5% of OPKO Health shares are held by institutional investors. 40.9% of OPKO Health shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares ORIC Pharmaceuticals and OPKO Health's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ORIC PharmaceuticalsN/AN/AN/A
OPKO Health-9.79%-2.61%-1.80%

Summary

ORIC Pharmaceuticals beats OPKO Health on 6 of the 9 factors compared between the two stocks.

ORIC Pharmaceuticals (NASDAQ:ORIC) and Corcept Therapeutics (NASDAQ:CORT) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, earnings, risk and valuation.

Profitability

This table compares ORIC Pharmaceuticals and Corcept Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ORIC PharmaceuticalsN/AN/AN/A
Corcept Therapeutics30.73%25.38%23.16%

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for ORIC Pharmaceuticals and Corcept Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ORIC Pharmaceuticals01602.86
Corcept Therapeutics01102.50

ORIC Pharmaceuticals presently has a consensus price target of $43.7143, suggesting a potential upside of 122.01%. Corcept Therapeutics has a consensus price target of $24.00, suggesting a potential upside of 7.00%. Given ORIC Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts plainly believe ORIC Pharmaceuticals is more favorable than Corcept Therapeutics.

Insider & Institutional Ownership

73.4% of ORIC Pharmaceuticals shares are held by institutional investors. Comparatively, 75.4% of Corcept Therapeutics shares are held by institutional investors. 16.4% of Corcept Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Valuation & Earnings

This table compares ORIC Pharmaceuticals and Corcept Therapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ORIC PharmaceuticalsN/AN/AN/AN/AN/A
Corcept Therapeutics$306.49 million8.59$94.18 million$0.7729.13

Corcept Therapeutics has higher revenue and earnings than ORIC Pharmaceuticals.

Summary

Corcept Therapeutics beats ORIC Pharmaceuticals on 6 of the 9 factors compared between the two stocks.

Intra-Cellular Therapies (NASDAQ:ITCI) and ORIC Pharmaceuticals (NASDAQ:ORIC) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends and earnings.

Profitability

This table compares Intra-Cellular Therapies and ORIC Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Intra-Cellular Therapies-1,985.32%-48.27%-42.56%
ORIC PharmaceuticalsN/AN/AN/A

Analyst Ratings

This is a breakdown of current ratings for Intra-Cellular Therapies and ORIC Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Intra-Cellular Therapies00703.00
ORIC Pharmaceuticals01602.86

Intra-Cellular Therapies presently has a consensus price target of $47.4286, suggesting a potential upside of 49.57%. ORIC Pharmaceuticals has a consensus price target of $43.7143, suggesting a potential upside of 122.01%. Given ORIC Pharmaceuticals' higher possible upside, analysts plainly believe ORIC Pharmaceuticals is more favorable than Intra-Cellular Therapies.

Insider and Institutional Ownership

79.1% of Intra-Cellular Therapies shares are held by institutional investors. Comparatively, 73.4% of ORIC Pharmaceuticals shares are held by institutional investors. 18.2% of Intra-Cellular Therapies shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Intra-Cellular Therapies and ORIC Pharmaceuticals' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Intra-Cellular Therapies$60,000.0042,764.63$-147,720,000.00($2.68)-11.83
ORIC PharmaceuticalsN/AN/AN/AN/AN/A

ORIC Pharmaceuticals has lower revenue, but higher earnings than Intra-Cellular Therapies.

Summary

Intra-Cellular Therapies beats ORIC Pharmaceuticals on 5 of the 9 factors compared between the two stocks.

Deciphera Pharmaceuticals (NASDAQ:DCPH) and ORIC Pharmaceuticals (NASDAQ:ORIC) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends and earnings.

Profitability

This table compares Deciphera Pharmaceuticals and ORIC Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Deciphera PharmaceuticalsN/A-45.02%-40.12%
ORIC PharmaceuticalsN/AN/AN/A

Analyst Ratings

This is a breakdown of current ratings for Deciphera Pharmaceuticals and ORIC Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Deciphera Pharmaceuticals03702.70
ORIC Pharmaceuticals01602.86

Deciphera Pharmaceuticals presently has a consensus price target of $70.30, suggesting a potential upside of 59.59%. ORIC Pharmaceuticals has a consensus price target of $43.7143, suggesting a potential upside of 122.01%. Given ORIC Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe ORIC Pharmaceuticals is more favorable than Deciphera Pharmaceuticals.

Insider and Institutional Ownership

73.6% of Deciphera Pharmaceuticals shares are held by institutional investors. Comparatively, 73.4% of ORIC Pharmaceuticals shares are held by institutional investors. 7.0% of Deciphera Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Deciphera Pharmaceuticals and ORIC Pharmaceuticals' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Deciphera Pharmaceuticals$25 million101.54$-192,260,000.00($4.48)-9.83
ORIC PharmaceuticalsN/AN/AN/AN/AN/A

ORIC Pharmaceuticals has lower revenue, but higher earnings than Deciphera Pharmaceuticals.

Rocket Pharmaceuticals (NASDAQ:RCKT) and ORIC Pharmaceuticals (NASDAQ:ORIC) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends and earnings.

Profitability

This table compares Rocket Pharmaceuticals and ORIC Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Rocket PharmaceuticalsN/A-35.81%-27.52%
ORIC PharmaceuticalsN/AN/AN/A

Analyst Ratings

This is a breakdown of current ratings for Rocket Pharmaceuticals and ORIC Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Rocket Pharmaceuticals011302.93
ORIC Pharmaceuticals01602.86

Rocket Pharmaceuticals presently has a consensus price target of $59.1818, suggesting a potential upside of 44.45%. ORIC Pharmaceuticals has a consensus price target of $43.7143, suggesting a potential upside of 122.01%. Given ORIC Pharmaceuticals' higher possible upside, analysts plainly believe ORIC Pharmaceuticals is more favorable than Rocket Pharmaceuticals.

Insider and Institutional Ownership

73.4% of ORIC Pharmaceuticals shares are held by institutional investors. 41.4% of Rocket Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Rocket Pharmaceuticals and ORIC Pharmaceuticals' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Rocket PharmaceuticalsN/AN/A$-77,270,000.00($1.58)-25.93
ORIC PharmaceuticalsN/AN/AN/AN/AN/A

Summary

ORIC Pharmaceuticals beats Rocket Pharmaceuticals on 4 of the 7 factors compared between the two stocks.


ORIC Pharmaceuticals Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Taro Pharmaceutical Industries logo
TARO
Taro Pharmaceutical Industries
1.1$72.59-0.3%$2.78 billion$644.77 million-10.36
OPKO Health logo
OPK
OPKO Health
1.9$4.06-3.0%$2.72 billion$901.90 million-22.55
Corcept Therapeutics logo
CORT
Corcept Therapeutics
1.5$22.43-1.1%$2.63 billion$306.49 million25.20
Intra-Cellular Therapies logo
ITCI
Intra-Cellular Therapies
1.7$31.71-0.1%$2.57 billion$60,000.00-9.85News Coverage
Deciphera Pharmaceuticals logo
DCPH
Deciphera Pharmaceuticals
1.6$44.05-0.5%$2.54 billion$25 million-8.81
Rocket Pharmaceuticals logo
RCKT
Rocket Pharmaceuticals
1.4$40.97-3.8%$2.53 billionN/A-22.51
Global Blood Therapeutics logo
GBT
Global Blood Therapeutics
1.4$39.97-2.0%$2.48 billion$2.11 million-8.65
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.6$9.29-1.1%$2.46 billion$182.24 million-8.08
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.6$144.90-5.9%$2.41 billion$120.28 million-146.36Decrease in Short Interest
Cryoport logo
CYRX
Cryoport
1.9$51.64-1.3%$2.36 billion$33.94 million-89.03
ALX Oncology logo
ALXO
ALX Oncology
1.9$57.95-10.0%$2.33 billionN/A0.00Increase in Short Interest
Amarin logo
AMRN
Amarin
1.6$5.84-1.5%$2.30 billion$429.76 million-116.78
Xencor logo
XNCR
Xencor
1.2$39.59-2.2%$2.29 billion$156.70 million-28.28News Coverage
Prestige Consumer Healthcare logo
PBH
Prestige Consumer Healthcare
1.6$44.30-1.2%$2.21 billion$963.01 million13.76News Coverage
Arcus Biosciences logo
RCUS
Arcus Biosciences
2.0$30.49-2.7%$2.16 billion$15 million-15.96
Dicerna Pharmaceuticals logo
DRNA
Dicerna Pharmaceuticals
1.8$26.18-0.3%$2.00 billion$23.90 million-16.26Analyst Revision
News Coverage
Revance Therapeutics logo
RVNC
Revance Therapeutics
1.7$27.91-0.8%$1.99 billion$410,000.00-6.07
Axsome Therapeutics logo
AXSM
Axsome Therapeutics
1.4$51.89-2.1%$1.94 billionN/A-19.29
IGM Biosciences logo
IGMS
IGM Biosciences
1.7$62.10-10.3%$1.91 billionN/A-26.43Increase in Short Interest
Gap Down
Kura Oncology logo
KURA
Kura Oncology
1.6$28.62-0.2%$1.89 billionN/A-17.56
NGM Biopharmaceuticals logo
NGM
NGM Biopharmaceuticals
1.8$24.53-3.7%$1.88 billion$103.54 million-18.44News Coverage
Madrigal Pharmaceuticals logo
MDGL
Madrigal Pharmaceuticals
1.7$117.02-0.0%$1.88 billionN/A-10.57
MORF
Morphic
1.1$57.73-2.8%$1.87 billion$16.98 million-37.01Decrease in Short Interest
News Coverage
Seres Therapeutics logo
MCRB
Seres Therapeutics
1.7$20.16-2.1%$1.85 billion$34.51 million-17.23
FibroGen logo
FGEN
FibroGen
1.8$19.89-6.6%$1.82 billion$256.58 million-7.62
MacroGenics logo
MGNX
MacroGenics
1.4$30.07-3.6%$1.80 billion$64.19 million-9.61Decrease in Short Interest
Pandion Therapeutics logo
PAND
Pandion Therapeutics
1.0$60.05-0.0%$1.77 billion$970,000.000.00News Coverage
Five Prime Therapeutics logo
FPRX
Five Prime Therapeutics
1.4$37.97-0.1%$1.77 billion$14.87 million-14.17Increase in Short Interest
Amneal Pharmaceuticals logo
AMRX
Amneal Pharmaceuticals
1.6$5.77-3.3%$1.73 billion$1.63 billion14.07Decrease in Short Interest
News Coverage
Cytokinetics logo
CYTK
Cytokinetics
1.7$23.85-1.3%$1.71 billion$26.87 million-12.49Insider Selling
News Coverage
Zentalis Pharmaceuticals logo
ZNTL
Zentalis Pharmaceuticals
1.8$40.42-7.4%$1.66 billionN/A0.00Analyst Report
News Coverage
Gap Down
Ironwood Pharmaceuticals logo
IRWD
Ironwood Pharmaceuticals
1.8$10.16-0.3%$1.64 billion$428.41 million14.72
Harmony Biosciences logo
HRMY
Harmony Biosciences
1.4$28.72-1.4%$1.63 billionN/A0.00
Aurinia Pharmaceuticals logo
AUPH
Aurinia Pharmaceuticals
1.8$12.64-1.3%$1.61 billion$320,000.00-8.60Analyst Report
ADC Therapeutics logo
ADCT
ADC Therapeutics
1.7$22.76-5.4%$1.57 billion$2.34 million-9.64
Myovant Sciences logo
MYOV
Myovant Sciences
1.3$17.18-5.6%$1.56 billionN/A-6.11Increase in Short Interest
News Coverage
Prelude Therapeutics logo
PRLD
Prelude Therapeutics
1.4$32.70-7.8%$1.52 billionN/A0.00
uniQure logo
QURE
uniQure
1.7$33.14-1.8%$1.49 billion$7.28 million-8.79
Heron Therapeutics logo
HRTX
Heron Therapeutics
1.7$16.29-1.9%$1.49 billion$145.97 million-6.60
Applied Molecular Transport logo
AMTI
Applied Molecular Transport
2.0$42.12-16.2%$1.48 billionN/A0.00
Travere Therapeutics logo
TVTX
Travere Therapeutics
1.3$24.52-4.4%$1.48 billion$175.34 million-14.42Analyst Report
News Coverage
Supernus Pharmaceuticals logo
SUPN
Supernus Pharmaceuticals
1.4$27.97-1.2%$1.48 billion$392.76 million11.61
Generation Bio logo
GBIO
Generation Bio
1.8$26.06-4.4%$1.47 billionN/A0.00Increase in Short Interest
Cassava Sciences logo
SAVA
Cassava Sciences
0.9$35.96-15.6%$1.43 billionN/A-149.83
ImmunoGen logo
IMGN
ImmunoGen
1.5$7.18-5.3%$1.43 billion$82.27 million-17.51
Kronos Bio logo
KRON
Kronos Bio
1.7$25.41-7.4%$1.42 billionN/A0.00Insider Selling
High Trading Volume
Unusual Options Activity
News Coverage
Aclaris Therapeutics logo
ACRS
Aclaris Therapeutics
0.8$27.46-5.5%$1.42 billion$4.23 million-20.34Increase in Short Interest
Endo International logo
ENDP
Endo International
1.3$6.17-0.5%$1.42 billion$2.91 billion-9.07News Coverage
ATBPD
Antibe Therapeutics
0.1$3.66-6.0%$1.42 billion$7.51 million-6.10
Cara Therapeutics logo
CARA
Cara Therapeutics
1.6$28.36-2.9%$1.41 billion$19.89 million-13.38
This page was last updated on 4/13/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.